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Abstract
It has recently been shown that fixed-dose-rate (gemcitabine) infusion may be superior to bolus gemcitabine in the
treatment of metastatic pancreas cancer. We wished to compare the radiosensitizing effects of fixed-dose-rate
gemcitabine infusion to standard bolus injection. We measured weight loss and mouse intestinal crypt survival
to determine equally toxic concentrations of gemcitabine administered through a 3-hour fixed-dose-rate infusion
versus bolus injection in combination with fractionated radiation. To measure the effect of fixed-dose-rate gemci-
tabine infusion or bolus injection on radiosensitization, we treated mice bearing Panc-1 xenografts with equally
toxic concentrations of gemcitabine (100 mg/kg fixed-dose-rate infusion or 500 mg/kg bolus injection) and fraction-
ated radiation and monitored tumor growth. We found that 100 mg/kg gemcitabine through fixed-dose-rate infu-
sion produced the same weight loss and intestinal crypt toxicity as the 500 mg/kg bolus injection. In nude mice
bearing Panc-1 xenografts, fixed-dose-rate gemcitabine infusion produced greater radiosensitization than bolus
injection with tumor doubling times of 44 ± 5 versus 29 ± 3 days, respectively (*P < .05). Fixed-dose-rate gemci-
tabine infusion produced enhanced radiosensitization without additional normal tissue toxicity compared to bolus
gemcitabine injection. These data support an ongoing clinical trial using fixed-dose-rate gemcitabine infusion com-
bined with conformal radiation in the treatment of locally advanced pancreatic cancer.
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Introduction
Chemoradiation is the standard treatment for locally advanced pan-
creas cancer [1]. For the last 12 years, we have investigated gemcita-
bine combined with radiation for the treatment of pancreatic cancer
both in the laboratory and the clinic. Our philosophy in the design
of clinical trials for pancreatic cancer has been to give the maximal
safe dose of radiation using optimal conformal techniques, along with
the best systemic therapeutic agent, which is also a radiation sensi-
tizer. This approach initially led us to combine gemcitabine with ra-
diation, because gemcitabine has been found to be more effective
than 5-fluorouracil for patients with locally advanced or metastatic
pancreas cancer [2], and gemcitabine is a potent radiation sensitizer
in pancreatic cancer cells [3]. Our first clinical studies established
the maximum safe dose of radiation (36 Gy in 2.4-Gy fractions) that
could be used with full-dose (1000 mg/m2) gemcitabine and sug-
gested that gemcitabine-radiation therapy was at least equal to,
if not better than, 5-fluorouracil-radiation therapy [4,5]. In a sub-
sequent trial, we added cisplatin, based on the clinical finding that
cisplatin-gemcitabine appeared to be superior to gemcitabine alone
for metastatic disease [6] and our preclinical study of cisplatin-
gemcitabine showing synergistic toxicity and equal radiosensitization
compared to gemcitabine [7]. Our clinical result suggested that the full
systemic dose of cisplatin and gemcitabine could be achieved in com-
bination with conformal tumor (as well as involved regional lymph
nodes) radiation, and that this combination may provide additional
benefit beyond that offered by gemcitabine and radiation [8].
While several studies were being conducted in an effort to increase
the effectiveness of gemcitabine-radiation therapy in pancreas cancer
[4,9,10], by means of additional drugs [8,11–13], investigations were
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also being conducted to determine whether fixed-dose-rate infusion
of gemcitabine might be more effective than the standard delivery of
gemcitabine through bolus infusion. The concept underlying this ap-
proach was based on pharmacokinetic studies which showed that
fixed-dose-rate gemcitabine infusion results in increased accumula-
tion of 2′,2′-difluorodeoxycytidine 5′-triphosphate (dFdCTP), an
active gemcitabine metabolite, in comparison to conventional gem-
citabine delivery [14,15]. This is related to the inhibition of deoxy-
cytidine kinase, the rate-limiting enzyme in gemcitabine metabolism,
which becomes saturated in response to the standard 30-minute
gemcitabine infusion. In contrast, fixed-dose-rate infusion of gemci-
tabine over 1 to 3 hours has been shown to prolong the steady state
plasma concentrations of gemcitabine within a range (10-20 μM)
that does not oversaturate deoxycytidine kinase and thus produces
increased dFdCTP accumulation. A randomized phase II trial con-
ducted by Tempero et al. [16] showed that fixed-dose-rate infusion
compared to standard infusion of gemcitabine in patients with pan-
creatic cancer resulted in two-fold higher levels of dFdCTP in circu-
lating mononuclear cells. Furthermore, their study suggested that
fixed-dose-rate infusion might offer some clinical benefit over the
standard bolus infusion of gemcitabine.
Because evidence suggested that fixed-dose-rate infusion of gemcita-
bine may be a better systemic therapy than standard bolus gemcitabine,
we reasoned that it would be of interest to explore this as a radiosensi-
tizing approach. We hypothesized that fixed-dose-rate infusion of gem-
citabine would be a more effective radiation sensitizer than bolus
injection of gemcitabine based on the higher levels of dFdCTP, and
presumably 2′,2′-difluorodeoxycytidine 5′-diphosphate (dFdCDP), as-
sociated with fixed-dose-rate infusion of gemcitabine. Therefore, we
carried out a study to assess whether fixed-dose-rate gemcitabine would
produce at least as good, if not a better therapeutic index as standard
bolus gemcitabine. We first determined comparable doses of gemcita-
bine for fixed-dose-rate infusion versus bolus injection using loss of
body weight as an end point. Because one of the main dose-limiting
toxicities for the combination of gemcitabine and radiation in the treat-
ment of pancreas cancer is gastrointestinal toxicity related to the loss of
intestinal crypts, we assessed the toxicity of fixed-dose-rate infusion and
bolus injection of gemcitabine in combination with radiation by mea-
suring the survival of intestinal crypts. We then compared the effects
of fixed-dose-rate infusion versus bolus injection gemcitabine on the
growth of subcutaneous pancreatic cancer tumor xenografts.
Materials and Methods
Cell Lines and Drug Administration
The human pancreatic adenocarcinoma cell line Panc-1 was ob-
tained from American Type Culture Collection (Manassas, VA) and
was maintained in RPMI 1640 medium with 10% cosmic calf serum
(Hyclone, Logan, UT) and antibiotics at 37°C in 5% CO2. Gemcita-
bine (a gift from Eli Lilly, Indianapolis, IN) was dissolved in isotonic
saline and administered once as an intraperitoneal bolus injection
(500-1000 mg/kg) or as an intraperitoneal fixed-dose-rate infusion
(100-750 mg/kg at 0.012-0.09 mg/min over a period of 3 hours) in
animal studies. For the infusion, mice were anesthetized with a com-
bination of ketamine and xylazine and were placed on a warming blan-
ket to minimize heat loss. Core body temperatures were monitored
with a thermocouple probe (Physitemp, Clifton, NJ) to ensure no sig-
nificant change in temperature occurred during the infusion period.
Flow Cytometry
Cells were trypsinized, washed, and resuspended in PBS, fixed by
dropwise addition of ice-cold 70% ethanol, and stored at 4°C until
the day of analysis. Cells were then washed with PBS and suspended
in PBS containing 18 μg/ml propidium iodide and 40 μg/ml ribonu-
clease A. Samples were analyzed on an Elite flow cytometer (Coulter
Electronics, Hialeah, FL).
Clonogenic Cell Survival Assay
Clonogenic assays were performed using standard techniques as
described previously [17]. Radiation survival data from drug-treated
cells were corrected for plating efficiency using a nonirradiated plate
treated with drug under the same conditions. Cell survival curves
were fitted using the linear-quadratic equation, and the mean inacti-
vation dose was calculated according to the method of Fertil et al.
[18]. The cell survival enhancement ratio was calculated as the ratio
of the mean inactivation dose under control conditions divided by
the mean inactivation dose after drug exposure. A value significantly
greater than 1 indicates radiosensitization.
Irradiation
Irradiations were carried out using an X-ray unit (Pantak Therapax
DXT 300 Model; Pantak, East Haven, CT) at a dose rate of approxi-
mately 3 Gy/min. Dosimetry was carried out using an ionization
chamber connected to an electrometer system that is directly trace-
able to a National Institute of Standards and Technology calibration.
To assess toxicity (intestinal crypt assay), animals were given 5 or
15 Gy of whole-body radiation delivered in five equal fractions be-
ginning 24 hours post–gemcitabine treatment. Animals were main-
tained in restraints and positioned such that the secondary collimator
encompassed the entire dorsal surface of the animal. To measure effi-
cacy, two 6-Gy doses of radiation at 6 and 24 hours after gemcitabine
delivery were given directly to the tumor. Animals were placed in a
restraint that permitted them to remain conscious during the pro-
cedure and positioned such that the apex of each flank tumor was at
the center of a 2.4-cm aperture in the secondary collimator and irradi-
ated with the rest of the mouse being shielded from radiation.
Weight Loss Studies
Non–tumor-bearing C3H female mice were given gemcitabine by
fixed-dose-rate infusion or bolus injection. Body weight was recorded
for 1 week after gemcitabine treatment. The maximally tolerated
doses for both conditions were defined as those that produced ap-
proximately a 10% weight loss.
Intestinal Crypt Assay
The microcolony assay introduced by Withers and Elkind [19]
was used to determine the survival of crypt epithelial cells in the
jejunum of mice exposed to whole-body irradiation (WBI). Non–
tumor-bearing C3H female mice were given gemcitabine, and then
on the following day, were exposed to fractionated daily WBI. Whole-
body irradiation was delivered as 1- or 3-Gy daily fractions in the
morning for 5 consecutive days for a total dose of 5 or 15 Gy, respec-
tively. Mice were euthanized 66 hours after the fifth radiation dose. A
2-cm section of the jejunum was fixed in neutral-buffered formalin
and was prepared for histologic examination. The regenerating crypts
in the jejunal cross-section were microscopically counted at a mag-
nification of ×100 on hematoxylin and eosin–stained sections cut
at a thickness of 4 μm. Data are presented as the average surviving
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fractions of the initial number of crypts per circumference in control
for each group against the dose of WBI from three to four animals per
treatment group with four sections of the jejunum from each animal
and three circumferences per section.
Tumor Growth Studies
Panc-1 cells (5 × 106) were transplanted subcutaneously into the
flank of Athymic Nude-Foxn1nu mice (Harlan, Indianapolis, IN).
Treatment was started once a tumor reached 100 mm3. Animals were
given gemcitabine and then two 6-Gy doses of radiation at 6 and
24 hours after gemcitabine treatment. Body weight and tumor size
were measured three times per week. Tumor volume (TV) was calcu-
lated according to the equation for a prolate spheroid: TV ¼ π6 ab
2
 
,
where a and b are the longer and shorter dimensions of the tumor,
respectively. Data are expressed as the ratio of tumor volume at varying
times after treatment compared to the first day of treatment (day 0).
Measurements were made until day 60 or until the tumor volume in-
creased by approximately a factor of 8, at which point the animals were
sacrificed to avoid potential discomfort. Animals were handled ac-
cording to the established procedures of the University of Michigan
Laboratory Animals Maintenance Manual.
Statistics
Statistically significant differences were determined using the Stu-
dent’s t test. Statistical significance was defined at P < .05.
Results
To confirm that a relatively brief exposure to gemcitabine could
produce radiosensitization in pancreatic cancer cells, we began by de-
termining if a 2-hour gemcitabine exposure could produce S-phase
redistribution and radiosensitization. We confirmed in Panc-1 cells
that equicytotoxic (approximately 50% survival) doses of gemcita-
bine administered as either a 24-hour incubation, which we have
used in the past [3], or a 2-hour incubation followed by a 24-hour
culture without drug resulted in redistribution of cells into early
S-phase (Figure 1A). Furthermore, we found that either short or long
gemcitabine exposure resulted in radiosensitization, with mean radi-
ation enhancement ratios (± SEM) of 1.5 ± 0.2 and 1.8 ± 0.2 (n = 3),
respectively (Figure 1B). Therefore, we conclude that the radiosensi-
tization produced by a brief exposure to a high concentration of gem-
citabine compared to a longer exposure to a lower concentration of
gemcitabine is similar.
Our goal in the animal studies was to examine the relative efficacy
of fixed-dose-rate infusion gemcitabine compared to bolus injection
gemcitabine under the maximally tolerated dose for both conditions.
In response to a single dose of gemcitabine through fixed-dose-rate or
bolus injection, animals experienced weight loss during the first week
after treatment but then recovered by 8 to 10 days after gemcitabine
exposure. We found that a dose of 100 mg/kg given as a fixed-dose-
rate infusion or 500 mg/kg given as a bolus injection produced similar
toxicity, which established the doses to be used for the subsequent stud-
ies of intestinal toxicity and tumor growth delay (Figure 2).
To compare the intestinal tissue toxicity of the two types of drug
administration with radiation therapy, we used the jejunal crypt assay.
This seemed appropriate in the context of optimizing treatment of
pancreatic cancer, because the small intestine is in the radiation treat-
ment portal. Mice were treated with a single dose of gemcitabine by
fixed-dose-rate infusion or bolus injection, and on the next day, radi-
ation treatments were initiated. We used either 5 or 15 Gy given in
five fractions, which alone produced a decrease in the number of
crypts. Both drug regimens (100 mg/kg infusion or 500 mg/kg bolus
injection), when combined with radiation, resulted in greater dam-
age to the jejunum than did radiation alone but were not significantly
different from each other (Figure 3). In the absence of radiation, gem-
citabine alone through fixed-dose-rate infusion or bolus injection pro-
duced similar effects on crypt survival. These findings, combined with
the measured weight loss, suggested that we had established approxi-
mately equally toxic and maximally tolerable conditions.
We then compared the effects of these two equitoxic treatments on
the growth of Panc-1 tumors after radiation treatment. To maximize
the radiosensitizing potential of gemcitabine, radiation was given (in
Figure 1. The effect of short versus long gemcitabine exposure on
cell cycle distribution and radiosensitization. Panc-1 cells were
treated with the equicytotoxic concentrations of gemcitabine
(Gem) for 2 or 24 hours (1 μM and 300 nM, respectively). (A) Cells
were processed for flow cytometry 24 hours after the start of gem-
citabine exposure. Human lymphocytes were included as an inter-
nal standard. (B) Alternatively, cells were treated with 0- to 6-Gy
irradiation 24 hours from the start of gemcitabine exposure. After
radiation exposure, cells were processed for clonogenic survival
as described in Materials and Methods. Data are from a single ex-
periment representative of n = 3 experiments. The mean radiation
enhancement ratios ± SEM (n = 3) for short or long gemcitabine
exposures were 1.5 ± 0.2 and 1.8 ± 0.2, respectively. These val-
ues were significantly different from irradiated, non–drug-treated
controls (P < .05) but not significantly different from each other.
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two 6-Gy fractions) within the first 24 hours after gemcitabine treat-
ment. We found that neither method of gemcitabine administration
alone resulted in a significant slowing of tumor growth. As expected,
radiation alone delayed tumor growth. The use of bolus gemcita-
bine caused modest radiosensitization, but radiosensitization pro-
duced by fixed-dose-rate infusion gemcitabine was greater (Figure 4).
This is evidenced by a significantly slower tumor doubling time of
44 ± 5 days in animals treated with radiation and gemcitabine by
fixed-dose-rate infusion gemcitabine compared to the tumor dou-
bling time of 29 ± 3 days in animals treated with radiation and a
bolus gemcitabine injection. None of these treatment conditions were
Figure 2. The effect of gemcitabine dose on the weight of tumor-free mice after fixed-dose-rate infusion or bolus injection gemcitabine.
Mice were untreated or treated with 100- to 750-mg/kg gemcitabine by fixed-dose-rate infusion or with 500 to 1000 mg/kg by bolus
injection. Total body weight was measured 10 days after treatment. Data are expressed as the percentage of the initial starting weight
and are shown as the mean of three to five animals per treatment group.
Figure 3. The effect of fixed-dose-rate versus bolus gemcitabine
infusion with radiation on jejunal crypt survival. Mice were treated
with 100-mg/kg gemcitabine through fixed-dose-rate infusion or
with 500-mg/kg gemcitabine through bolus injection. Twenty-
four hours after gemcitabine treatment, mice were given fraction-
ated daily whole-body radiation (RT) (5 and 15 Gy at 1 or 3 Gy/day
for 5 days, respectively) and were euthanized 66 hours after the
fifth radiation dose. A section of the jejunum was fixed, and
regenerating crypts were counted. Data are presented as the
mean surviving fraction of crypts per circumference relative to
the untreated control animals for each group (n = 3-4 animals
per treatment group; four sections per animal were averaged to
obtain a single value for each animal). There were statistically sig-
nificant differences among the untreated, the radiation-treated,
and the radiation- plus gemcitabine-treated groups (n = 3-4; P <
.05); however, there was no significant difference between gem-
citabine fixed-dose-rate infusion and bolus injection either in the
absence or in the presence of 5- or 15-Gy radiation.
Figure 4. The effect of fixed-dose-rate versus bolus injection gem-
citabine on pancreatic tumor xenograft growth. Nude mice bearing
Panc-1 tumor xenografts were treated with 100-mg/kg gemcitabine
through fixed-dose-rate infusion or with 500-mg/kg gemcitabine
through bolus injection. Mice were then exposed to 12-Gy radiation
given in two fractions at 6 and 24 hours post–gemcitabine treat-
ment. Tumor growth was measured for 60 days after treatment.
Data are presented as the mean tumor volume relative to the start-
ing volume on the first day of treatment (day 0) (untreated: n = 3,
RT: n=4, bolus: n=4, bolus+RT: n=5, infusion: n=4, infusion+
RT: n = 5). There was a statistically significant difference in the
time to tumor doubling between radiation plus gemcitabine fixed-
dose-rate infusion (44 ± 5 days) versus radiation plus gemcitabine
bolus injection (29 ± 3 days) (*P < .05).
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accompanied by significant weight loss, suggesting minimal normal tis-
sue toxicity (Table 1).
Discussion
In this study, we have found that the combination of radiation and
fixed-dose-rate gemcitabine produced a better therapeutic index than
radiation plus standard bolus gemcitabine. As the main goal of this
work was to design an improved treatment for pancreatic cancer, we
used a human pancreas tumor xenograft model to assess efficacy.
Because the major dose-limiting toxicity for the combination of gem-
citabine and radiation in the treatment of pancreas cancer is gastro-
intestinal (specifically, duodenal), we chose weight loss and an
assessment of intestinal crypts to measure toxicity. These findings,
when combined with previous clinical data suggesting that fixed-
dose-rate gemcitabine might be superior to bolus gemcitabine as sys-
temic treatment, support the concept of fixed-dose-rate infusion of
gemcitabine as a reasonable option to explore in combination with
radiation in the treatment of locally unresectable pancreatic cancer.
There have been a number of attempts to improve the chemother-
apeutic effects of bolus gemcitabine alone for patients with metastatic
pancreatic cancer. A recent phase III clinical trial in pancreas cancer
compared the efficacy of the combination of cisplatin and gemcita-
bine to gemcitabine alone [20]. This study demonstrated a signifi-
cant improvement in progression-free survival and a trend toward
improvement in the overall survival for the combination of cisplatin
and gemcitabine compared to gemcitabine alone. We conducted a
phase I/II trial using a time to event continual reassessment model
to determine that essentially the same dose of cisplatin and gemcita-
bine as was used for metastatic disease could be given with conformal
radiation for patients with locally advanced disease and found a me-
dian survival of 13 months [8], which was promising compared to
historical controls [4].
Oxaliplatin has also been added to gemcitabine in an effort to im-
prove the treatment of advanced pancreatic cancer [21]. A randomized
phase III trial showed improved progression-free survival and a non-
statistically significant trend toward improved overall survival in patients
treated with gemcitabine-oxaliplatin versus gemcitabine alone. Based on
clinical data and our preclinical data that oxaliplatin and gemcitabine
show synergistic toxicity, and that radiosensitization is maintained, we
have initiated a phase I/II trial of oxaliplatin dose escalation in combi-
nation with gemcitabine-radiation. This combination was well tolerated
but whether it will be superior to gemcitabine-radiation therapy is not
yet determined. In the latter part of this study, an attempt will be made
to replace bolus gemcitabine with fixed-dose-rate gemcitabine, which is
supported by the results of this current study.
The radiosensitizing and cytotoxic properties of gemcitabine are
mediated by two distinct metabolites: dFdCDP and dFdCTP, respec-
tively. The diphosphorylated metabolite of gemcitabine, dFdCDP, is
a potent inhibitor of ribonucleotide reductase, resulting in reduced
synthesis of deoxynucleoside triphosphates, primarily deoxyadeno-
sine triphosphate. Previous studies have shown a correlation between
the doses of gemcitabine required to achieve maximal radiosensitiza-
tion and those that produced nearly complete deoxyadenosine tri-
phosphate pool depletion, whereas intracellular concentrations of
dFdCTP were found not to correlate with radiosensitization [22,23].
Instead, dFdCTP has been shown to mediate the cytotoxic properties of
gemcitabine through misincorporation of 2′,2′-difluorodeoxycytidine
5′-monophosphate into the DNA [24,25]. Together, these studies
suggest that dFdCDP mediates radiosensitization, whereas dFdCTP is
responsible for cytotoxicity. dFdCTP levels have been shown to accumu-
late at two-fold higher levels in the peripheral mononuclear blood cells of
patients that received fixed-dose-rate infusion gemcitabine versus bolus
gemcitabine [16]. Because dFdCDP is the precursor for dFdCTP and
the levels of these two metabolites have been shown to correlate [26], it
is likely that fixed-dose-rate infusion also results in elevated dFdCDP
levels. Moreover, it will be important in future studies to determine
whether fixed-dose-rate infusion gemcitabine also results in increased
tumor concentrations of dFdCTP or dFdCDP.
This study has some limitations. We chose to conduct the tumor
growth delay studies with a different radiation scheme than that used
in the toxicity studies. Whereas it would have been ideal to use the
same radiation schemes, this was not technically feasible. Mouse in-
testine is much more sensitive to radiation than implanted tumor.
We chose two 6-Gy fractions for the tumor growth delay experiments
because we wanted 1) to produce maximal radiosensitization, which
has been shown to occur in the first 24 hours after gemcitabine [22]
and 2) to avoid possible differences in gemcitabine metabolism for
the two different delivery methods that might have occurred over a
longer course of several radiation fractions and confounded the as-
sessment of radiosensitization. This dose (6 Gy × 2) of whole-body
radiation would result in a high mortality rate. Conversely, if we had
administered the tolerable whole-body dose (1 Gy or 3 Gy × 5) to
the tumor, we would not have expected to see substantial tumor re-
sponses. We feel that the conclusion of this experiment does not de-
pend on the particular dose of radiation, but on the fact that we
assessed the effects of the same doses of radiation for the two gem-
citabine delivery methods on tumor growth delay under conditions
in which the drug-radiation combination was equally toxic.
In the present study, we used an intraperitoneal bolus injection of
gemcitabine. However, the standard administration of gemcitabine
in the clinic is through a 30-minute intravenous infusion. Because
we were interested in the basic principle of a short versus a longer
gemcitabine administration, we elected to compare an intraperitoneal
bolus injection to a 3-hour fixed-dose-rate intraperitoneal infusion.
Although an intraperitoneal injection results in a slower uptake than
an intravenous bolus injection, it is likely that the pharmacokinetics
of a bolus intraperitoneal injection are different from a 30-minute
intravenous infusion and that the pharmacokinetics in mice are dif-
ferent from humans. Therefore, whereas this study demonstrates that
fixed-dose-rate infusion produces greater tumor radiosensitization
than bolus injection in mice, it should be followed up with clinical
trials to test this hypothesis in patients.
This study suggests that fixed-dose-rate gemcitabine should be ex-
plored to try to improve the outcome of treatment for pancreatic
cancer and supports the incorporation of fixed-dose-rate gemcitabine
into future clinical trials. This is consistent with our approach to clin-
ical trial design with the goal of improving systemic therapy while
Table 1. Relative* Weight After Therapy.
Treatment Day 2 Day 7
Untreated 1.02 ± 0.01 1.05 ± 0.02
RT 0.99 ± 0.02 1.03 ± 0.01
Injection 1.03 ± 0.06 1.07 ± 0.06
Injection + RT 0.98 ± 0.03 1.12 ± 0.06
Infusion 1.00 ± 0.01 0.99 ± 0.01
Infusion + RT 1.01 ± 0.02 0.96 ± 0.02
*Weights are relative to the first day of treatment (day 0).
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maintaining optimal local therapy. However, since a recent analysis
suggests that, with long-term follow-up, a substantial minority of pa-
tients will still have local failure [27], improvement in local control
should also be sought. This could be achieved through improved
radiosensitization, such as might be achieved by fixed-dose-rate gem-
citabine or potentially by improved technical approaches such as the
use of intensity-modulated radiotherapy (IMRT). It is plausible that
IMRTmight play a role in this context, as bowel toxicity is the major
toxicity, and might permit even more intense dose systemic therapy
with full-dose radiation therapy. However, we feel that these efforts
using IMRT should only be done in the context of a clinical trial. We
have recently initiated such a study.
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